RPL17 and non-small cell lung carcinoma: IgG1 and IgG4 antibodies that can target the PD-L1/PD-1 axis for NSCLC in combinational first line therapy includes atezolizumab, avelumab, durvalumab, cemiplimab, nivolumab, and pembrolizumab [140].